Harry Evans

Commercial

• a global bank on procuring the IT infrastructure necessary for its new digital bank in Hong Kong. The matter involved negotiating over 11 separate IT supply agreements, for the infrastructure, platform and software necessary for the new digital bank, with some of the biggest and most advanced global tech companies
• a global bank on the global re-structuring of its IP/technology portfolio, and the preparation of a suite of template agreements for managing its IP portfolio
• a major telecommunications company on the outsourcing of its customer experience platform to Amdocs
• a major Southeast Asia ride-hailing and Super-App company on procuring the IT infrastructure necessary for its new digital bank in Singapore
• Europe’s leading payments processing company in relation to various commercial arrangements for the provision of payments processing services to merchants globally, including BIN Sponsorship Agreements, Merchant Agreements, Payment Facilitator Agreements
• SES New Skies Satellite/iForte consortium in relation to an RFP released by Indonesian government to construct, launch and operate a multifunction communication satellite, as well as the associated ground network required for operating the satellite

• a European-based distribution company on in-licensing six biosimilars, for development and commercialisation across a number of Asian jurisdictions
• a European-based distribution company on acquiring from Sanofi the rights to commercialise a therapeutic product, and a portfolio of over-the-counter essential remedies, in a number of APAC jurisdictions.
• Janssen on the renegotiation of a suite of distribution agreements in relation to the distribution of a pulmonary artery hypertension medication in Philippines, Thailand and Vietnam
• an Indian based pharmaceutical company on entering into a long term, high-value licensing, development and commercialisation agreement (and related manufacturing agreement) with Mabion
• Lupin, an Indian based pharmaceutical company on the US$526 million divestment of Kyowa Pharmaceuticals Industry to Unison Capital Partners, and entering into long term product supply, product development, and transitional services agreements
• Strides Pharma, an Indian based pharmaceutical company, on the preparation and negotiation of a long-term, high value exclusive product supply agreement, relating to the divestment of various Australian assets
• an Indian vaccine manufacturer on entering into a high-value manufacturing and supply agreement relating to Covid-19 vaccines

Corporate

• major Southeast Asia ride-hailing and Super-App company, in relation to the due diligence of its technology and intellectual property assets for the purposes of identifying red-flag issues, and assisting it with remediating the same, ahead of its US$40b US listing
• a global US-based SuperApp on entering into a JV agreement with a Korean-based partner, for the purposes of exploiting a combined product and service offering. Arrangement included negotiation of long-term, high value software licence and services agreement and complex brand licensing arrangements
• a global US-based SuperApp on a number of fintech matters as it seeks to monetize its platforms, and a number of commercial arrangements across South East Asia (and India and China) by which the fintech products and services of various third parties have been promoted through, or incorporated onto, its platforms
• a leading UK retail bank on its strategic partnership with an innovative fintech company to accelerate the digital transformation of the Bank's business, including the procurement of IT infrastructure necessary for a new, cloud-native core banking platform and the Bank's participation in the fintech's Series A investment funding round

• a private equity investor on a significant investment into the biosimilars business of Viatris, a global pharmaceutical company
• a private equity investor on a significant investment into an India-headquartered pre-clinical and clinical research organisation, which included significant assets across Asia and the US
• a private equity investor on a significant investment into an India-headquartered biosimilar business, which included significant manufacturing and other infrastructure assets across Southeast Asia
• Everstone Group on its investment into AUM Biosciences. AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company that uses the power of precision medicine and digital health (including AI) to enhance the early-stage development of innovative treatment of cancers prevalent in Asia
• a European-based distribution company on the acquisition of a Southeast Asia-based medical device company
• Novartis on the IP issues associated with the sale of its vaccines business to GSK for US$7bn, the purchase of GSK’s oncology business for US$16bn, and the sale of Novartis’ flu business to CSL for $275 million. Resolved myriad IP issues over 3-year (and ongoing) period
• Accord Healthcare and Intas Pharmaceuticals on their $750 million acquisition of Actavis’ UK and Irish businesses from Teva
• Takeda on the competitive auction of Takeda's respiratory drugs portfolio to AstraZeneca for $575 million
• a China-based pharma company on the acquisition of a cancer care clinic business in Singapore
• a bidder in relation to its bid for Icon Group, an integrated cancer care, pharmaceutical services, and pharmaceutical compounding business, operating across China, Hong Kong, Singapore, Vietnam, Australia and New Zealand
• Sainsbury’s in relation to the divestment of its in-store pharmacy business to Lloyds Pharmacy
• Morgan Stanley Asia Limited and UBS, as joint sponsors, on the proposed listing of a leading Chinese biotech company, Brii Biosciences, on the Hong Kong Stock Exchange. The matter involved analysing a number of high value and multi-jurisdictional in-licensing arrangements
• Goldman Sachs and JP Morgan as joint sponsors of the listing of a leading Chinese biotech company, Antengene, on the Hong Kong Stock Exchange. The matter involved analysing a number of high value and multi-jurisdictional in-licensing arrangements